Abstract | INTRODUCTION: OBJECTIVE: RESULTS: We report two cases of successful intra-lesional injections of STS. A 44-year-old woman, with a history of dermatomyositis, presenting large subcutaneous calcifications in the right elbow, and a 42-year-old man, with a history of familial tumoral calcinosis, presenting large intramuscular calcifications in the right buttock, received weekly intra-lesional of 1-3g STS injections for 12 and 21 months, respectively. In both cases, the treatment relieved pain and greatly reduced the tumoral calcinosis with a very significant functional improvement without specific adverse effects. In case 1, TC size decreased from 28.7*56.0mm at baseline to 21.5*30.6mm at M12 treatment (59% reduction). In case 2, TC reduced from 167.5*204.3mm at baseline to 86.2*85.2mm at M21 treatment (79% reduction). CONCLUSION: Local injection of STS could be a promising therapeutic strategy for large and deep TC lesions and could therefore be an alternative to surgery.
|
Authors | J Goossens, M Courbebaisse, E Caudron, C Bahans, V Vacquerie, J Melchior, P Vergne Salle, C Moesch, M Daudon, V Frocht, P Richette, Hang-Korng Ea, V Guigonis |
Journal | Seminars in arthritis and rheumatism
(Semin Arthritis Rheum)
Vol. 47
Issue 3
Pg. 451-455
(12 2017)
ISSN: 1532-866X [Electronic] United States |
PMID | 28779847
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2017 Elsevier Inc. All rights reserved. |
Chemical References |
- Chelating Agents
- FGF23 protein, human
- Thiosulfates
- Fibroblast Growth Factor-23
- sodium thiosulfate
|
Topics |
- Adult
- Calcinosis
(drug therapy, etiology)
- Chelating Agents
(administration & dosage)
- Dermatomyositis
(complications, diagnostic imaging, drug therapy)
- Female
- Fibroblast Growth Factor-23
- Humans
- Hyperphosphatemia
(complications, drug therapy, genetics)
- Injections, Intralesional
- Magnetic Resonance Imaging
- Male
- Sjogren's Syndrome
(complications)
- Thiosulfates
(administration & dosage)
|